Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impac...
Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Two studies recently suggested the potential benefit of renin-angiotensin system (RAS) blockers (angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)) after AKI [3, 4]. Table 1 Patient characteristics ACEi/ARB + (N = 45) ACEi/ARB - (N = 303) p Characteristic at ICU admission Age—years 64.4 ± 15.1 63.1 ± 14.7 0.6...
Alternative Titles
Full title
Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_956871a28a6a4bacb049820e29ce96db
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_956871a28a6a4bacb049820e29ce96db
Other Identifiers
ISSN
1364-8535
E-ISSN
1364-8535,1466-609X,1366-609X
DOI
10.1186/s13054-019-2447-0
